ResMed (ASX: RMD) Shares Evaluated for Future Growth Prospects

2 min read | November 08, 2024 03:02 PM AEDT | By Team Kalkine Media

Google News:

ResMed (ASX: RMD) Shares Evaluated for Future Growth Prospects — Image source: Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights:

ResMed's Strong Financial Performance: A reported 13.6% compound annual growth rate (CAGR) in revenue over the last three years and a 29.1% CAGR in profit.

Debt-Free Capital Structure: The company has a net cash position of $624 million, and a debt/equity ratio of 18.0%, indicating low leverage.

Undervalued Based on Historical Price-Sales Ratio: ResMed shares are currently trading at a price-sales ratio of 5.20x, below their 5-year average of 8.70x.

ResMed (ASX:RMD) has demonstrated impressive financial growth in 2024, with its share price rising by 47.07%. To gauge the value of ResMed shares, it's essential to assess the company’s financial health, profitability, and market metrics.

ResMed, headquartered in San Diego, operates in the global medical equipment sector, specializing in sleep apnea treatment through its CPAP machines and providing software services for out-of-hospital care. The company reported annual revenue of $4.685 billion, reflecting a robust 13.6% growth rate over the last three years. This revenue growth has been complemented by a healthy gross margin of 57.4%, underscoring the profitability of its core products.

Profitability has also improved significantly. For the most recent financial year, ResMed recorded a profit of $1.021 billion, up from $475 million three years ago, highlighting a CAGR of 29.1%. This reflects the company’s ability to generate higher returns on its sales, a crucial metric for assessing financial health.

ResMed’s capital structure is also strong, with a net cash position of $624 million, indicating a surplus of cash over debt. This is a positive signal for financial stability, especially in periods of economic uncertainty. The company’s low debt/equity ratio of 18.0% further suggests it is conservatively leveraged, with more equity than debt.

One of the key valuation metrics to assess ResMed's market position is its price-sales ratio, which currently stands at 5.20x. This is significantly below its 5-year average of 8.70x, suggesting that the company’s shares are priced lower relative to its revenue growth compared to historical trends.

In summary, ResMed presents a strong financial outlook with growing profitability, a solid capital structure, and a relatively attractive market valuation based on its historical metrics.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.